NB Capital is focused on providing value add investments to even the largest institutional investor with internal healthcare capabilities. Much asset management today is disguised and leveraged high-cost beta. We are committed to providing clear-cut documented value add and nothing else.

NB Capital has developed a methodology to systematically capitalize the global information and data overload, biased incentives and irrationalities in the complex biopharma area. The methodology has been refined over 21 years in the biopharmaceutical area, from seed to 150 bln.USD market cap companies in this huge market cap sector. The aim is to find truly low risk investments (defined as low risk of losing capital) with a potential upside to be captured over a 2-3 year time frame, all tailored to the investors risk-tolerance. This approach has been validated with multiyear performance in the context of very large investors with existing beta-exposure in global equities.

For more information about NB Capital and this approach, please contact Florian Schönharting, Chief Investment Officer, +45 27293200